Stocks and Investing Stocks and Investing
Wed, March 2, 2022
Tue, March 1, 2022

David Lebowitz Initiated (BPMC) at Hold on, Mar 1st, 2022


Published on 2024-10-27 19:53:55 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Initiated "Blueprint Medicines Corporation" (BPMC) at Hold on, Mar 1st, 2022.

David has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 4 analyists that currently disagree with David


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
  • Bradley Canino of "Stifel" Upgraded from Hold to Strong Buy and Decreased Target to $95 on, Tuesday, January 25th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021
Contributing Sources